Form 13-F position report

PHARMACYTE BIOTECH INC COM NEW

Reported by MORGAN STANLEY

PMCB CUSIP 71715X203 Manager CIK 0000895421

Reported 0 shares, down 1 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 16 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 170000
2022-03-31 142000
2022-06-30 6000
2022-09-30 0
2022-12-31 161
2023-03-31 90
2023-06-30 60
2023-09-30 8
2023-12-31 9
2024-03-31 9
2024-06-30 7
2024-09-30 5
2024-12-31 4
2025-03-31 2
2025-06-30 0
2025-09-30 10
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for PHARMACYTE BIOTECH INC COM NEW held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -9 (-100.0%) 0 $0 2026-02-13
Q3 2025 New 9 +9 (0.0%) < 0.01% $10 2025-11-14
Q2 2025 Reduced 0 -1 (-100.0%) 0 $0 2025-08-15
Q1 2025 Reduced 1 -1 (-50.0%) < 0.01% $2 2025-05-15
Q4 2024 Unchanged 2 0 (0.0%) < 0.01% $4 2025-02-14
Q3 2024 Reduced 2 -1 (-33.3%) < 0.01% $5 2024-11-14
Q2 2024 Unchanged 3 0 (0.0%) < 0.01% $7 2024-08-14
Q1 2024 Reduced 3 -1 (-25.0%) < 0.01% $9 2024-05-15
Q4 2023 Added 4 +1 (33.3%) < 0.01% $9 2024-02-13
Q3 2023 Reduced 3 -18 (-85.7%) < 0.01% $8 2023-11-15
Q2 2023 Reduced 21 -10 (-32.3%) < 0.01% $60 2023-08-14
Q1 2023 Reduced 31 -24 (-43.6%) < 0.01% $90 2023-05-15
Q4 2022 Added 55 +24 (77.4%) < 0.01% $161 2023-02-14
Q3 2022 Reduced 31 -2,495 (-98.8%) 0 $0 2022-11-14
Q2 2022 Reduced 2,526 -59,343 (-95.9%) < 0.01% $6,000 2022-08-15
Q1 2022 Reduced 61,869 -6,264 (-9.2%) < 0.01% $142,000 2022-05-13
Q4 2021 Added 68,133 +67,102 (6508.4%) < 0.01% $170,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

26 managers reported PHARMACYTE BIOTECH INC COM NEW for Q2 2025.

Managers reporting PHARMACYTE BIOTECH INC COM NEW in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Reduced 194,447 -71 < 0.01% $213,892 15 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 126,603 -12,332 < 0.01% $139,277 16 qtrs
EQUITEC PROPRIETARY MARKETS LLC Unchanged 82,727 0 0.09% $90,172 15 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 49,800 +300 < 0.01% $54,282 9 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Added 27,606 +9,200 < 0.01% $30,367 7 qtrs
Schonfeld Strategic Advisors LLC Added 26,200 +700 < 0.01% $28,558 16 qtrs
UBS Group AG Added 22,591 +10,675 < 0.01% $24,624 16 qtrs
DIMENSIONAL FUND ADVISORS LP Unchanged 20,299 0 < 0.01% $22,329 10 qtrs
NORTHERN TRUST CORPORATION Unchanged 19,208 0 < 0.01% $20,937 15 qtrs
NATIONAL BANK OF CANADA FI Unchanged 3,300 0 < 0.01% $3,564 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 15, 2025
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.